Alnylam: HELIOS-A Phase 3 Study Of Vutrisiran Meets All Seco

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) said the HELIOS-A phase 3 study of vutrisiran met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis

Related Keywords

Washington , United States , Rena Denoncourt , Alnylam Pharmaceuticals Inc , , Vice President , Alnylam , Helios , Hase , Study , Vutrisiran , Meets , Secondary , Endpoints , Months ,